WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience Join the Society for Neuroscience
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, November 9, 2005, 25(45):10502-10509; doi:10.1523/JNEUROSCI.3016-05.2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gonzalez-Alegre, P.
Right arrow Articles by Paulson, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gonzalez-Alegre, P.
Right arrow Articles by Paulson, H. L.

 Previous Article  |  Next Article 

Neurobiology of Disease
Silencing Primary Dystonia: Lentiviral-Mediated RNA Interference Therapy for DYT1 Dystonia

Pedro Gonzalez-Alegre,1 Nicole Bode,1 Beverly L. Davidson,1,2 and Henry L. Paulson1

Departments of 1Neurology and 2Medicine, Carver College of Medicine at the University of Iowa, Iowa City, Iowa 52242

DYT1 is the most common inherited dystonia. Currently, there are no preventive or curative therapies for this dominantly inherited disease. DYT1 dystonia is caused by a common three-nucleotide deletion in the TOR1A gene that eliminates a glutamic acid residue from the protein torsinA. Recent studies suggest that torsinA carrying the disease-linked mutation, torsinA({Delta}E) acts through a dominant-negative effect by recruiting wild-type torsinA [torsinA(wt)] into oligomeric structures in the nuclear envelope. Therefore, suppressing torsinA({Delta}E) expression through RNA interference (RNAi) could restore the normal function of torsinA(wt), representing a potentially effective therapy regardless of the biological role of torsinA. Here, we have generated short hairpin RNAs (shRNAs) that mediate allele-specific suppression of torsinA({Delta}E) and rescue cells from its dominant-negative effect, restoring the normal distribution of torsinA(wt). In addition, delivery of this shRNA by a recombinant feline immunodeficiency virus effectively silenced torsinA({Delta}E) in a neural model of the disease. We further establish the feasibility of this viral-mediated RNAi approach by demonstrating significant suppression of endogenous torsinA in mammalian neurons. Finally, this silencing of torsinA is achieved without triggering an interferon response. These results support the potential use of viral-mediated RNAi as a therapy for DYT1 dystonia and establish the basis for preclinical testing in animal models of the disease.

Key words: dystonia; RNA interference; torsina; dyt1; gene therapy; FIV


Received July 21, 2005; revised September 23, 2005; accepted October 6, 2005.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
M. D. White, M. Farmer, I. Mirabile, S. Brandner, J. Collinge, and G. R. Mallucci
Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease
PNAS, July 22, 2008; 105(29): 10238 - 10243.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
J. W. Hewett, F. C. Nery, B. Niland, P. Ge, P. Tan, P. Hadwiger, B. A. Tannous, D. W.Y. Sah, and X. O. Breakefield
siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells
Hum. Mol. Genet., May 15, 2008; 17(10): 1436 - 1445.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. L. McBride, R. L. Boudreau, S. Q. Harper, P. D. Staber, A. M. Monteys, I. Martins, B. L. Gilmore, H. Burstein, R. W. Peluso, B. Polisky, et al.
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
PNAS, April 15, 2008; 105(15): 5868 - 5873.
[Abstract] [Full Text] [PDF]


Home page
Brief Funct Genomic ProteomicHome page
A. Jagannath and M. Wood
RNA interference based gene therapy for neurological disease
Brief Funct Genomic Proteomic, May 3, 2007; (2007) elm005v1.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-